Home >  News >  Industry >  Pharma News >  Biological E seeks DCGI...

Biological E seeks DCGI emergency use nod for Corbevax as booster in adults vaccinated with Covaxin, Covishield

According to the EUA application submitted to DCGI, Biological E in a phase-3 placebo-controlled clinical study, based on the drug regulator's nod, has evaluated the safety and immunogenicity of Corbevax as a single-dose booster in Covid-negative adults fully vaccinated with either Covishield or Covaxin.

By - Ruchika Sharma
Published On 2022-05-12 08:10 GMT   |   Update On 2024-02-16 06:05 GMT
Advertisement

New Delhi: Biological E has submitted an application to India's drug regulator seeking emergency use authorisation for its Covid vaccine Corbevax as a booster dose in adults fully vaccinated with Covishield or Covaxin, sources said on Wednesday.

The Drugs Controller General Of India (DCGI) had already approved Corbevax, India's first indigenously developed RBD protein subunit vaccine, for restricted use in emergency situations for those aged five and above.
Advertisement
Currently, it is being used to inoculate children in the age group of 12 to 14 years.
According to the EUA application submitted to DCGI, Biological E in a phase-3 placebo-controlled clinical study, based on the drug regulator's nod, has evaluated the safety and immunogenicity of Corbevax as a single-dose booster in Covid-negative adults fully vaccinated with either Covishield or Covaxin.
The study was conducted on 416 subjects aged 18 to 80 who were vaccinated with two doses of either Covaxin or Covishield with the last jab administered at least six months prior to giving the booster dose of Corbevax.
"The results showed a significant boost in immunogenicity in terms of neutralizing antibodies after 28 days when compared with placebo cohort in both Covishield and Covaxin arms.
"The safety profile of Corbevax was found similar to that of the earlier clinical trials," an official source told PTI quoting the Hyderabad-based firm as having mentioned in the EUA application.
The firm said, "We are now submitting the marketing authorization application for grant of permission Corbevax for restricted use in an emergency situation as a booster dose at six months after completion of primary immunization with two doses of Covishield or Covaxin in individuals aged 18 years and above."
As of now, the precaution dose is of the same COVID-19 vaccine used for administering the first and second doses.
India began administering precaution doses of Covid vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10.
The comorbidity clause was removed in March, making all people aged above 60 years eligible for the precaution dose of Covid vaccine.
India on April 10 began administering precaution doses of COVID-19 vaccines to all aged above 18 years at private vaccination centres.
All those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.

Read also: Govt to expedite process of recognition of Biological E Corbevax by other countries

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

AstraZeneca Pharma India bags CDSCO nod for expanded use of Trastuzumab Deruxtecan in HER2-Positive Solid Tumors

DoP identifies 11,100 Jan Aushadhi Kendras across India as Outdoor Cleaning Sites

Biocon Pharma, Carnegie Pharma gain USFDA tentative nod for Rifaximin Tablets to treat irritable bowel syndrome with diarrhea

Eli Lilly plans to invest over USD 1 billion in new contract manufacturing in India

Price Cap Exemption Pending: NPPA Refers Biodeal Pharma's Midazolam Nasal Spray to CDSCO, SNCM for Review

Zydus Gets CDSCO Panel Nod for Phase III Trial of Dextromethorphan, Phenylephrine Cough Syrup FDC

Toxic Coldrif Fallout: Tamil Nadu Govt Issues Show-Cause Notice to Sresan Pharma, License at Risk

Maharashtra B.Pharm Admissions 2025: 29,166 Students Allotted Seats in First Round